Search

Displaying results 1911 - 1920 of 2494 in total
  1. Drug

    Oxeclosporin

    go.drugbank.com/drugs/DB21134
    Experimental

    Oxeclosporin is a small molecule drug. The usage of the INN stem '-(clo)sporin' in the name indicates that Oxeclosporin is a cyclosporine derivative. Oxeclosporin has a monoisotopic molecular weight of 1261.86 Da.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  2. Drug

    Befetupitant

    go.drugbank.com/drugs/DB21149
    Experimental

    The usage of the INN stem '-pitant' in the name indicates that Befetupitant is a neurokinin NK1​ (substance P) receptor antagonist. Befetupitant has a monoisotopic molecular weight of 565.22 Da.

  3. Drug

    Oveporexton

    go.drugbank.com/drugs/DB21680
    Approved

    Oveporexton is an orally administered orexin receptor 2 (OX2R) agonist used to treat narcolepsy type 1 (NT1). NT1 is caused by the loss of orexin neuropeptide signaling, and oveporexton works by selectively activating OX2R to restore thi...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  4. Drug

    Fosrolapitant

    go.drugbank.com/drugs/DB21723
    Investigational

    The usage of the INN stem '-pitant' in the name indicates that Fosrolapitant is a neurokinin NK1​ (substance P) receptor antagonist. Fosrolapitant has a monoisotopic molecular weight of 654.16 Da.

  5. Drug

    Milsaperidone

    go.drugbank.com/drugs/DB24348
    ApprovedInvestigational

    Milsaperidone is an atypical antipsychotic agent that rapidly interconverts to iloperidone in vivo. Atypical antipsychotic agents work by blocking the D2 dopamine and serotonin receptor signalling pathways. Similarly, milsaperidone acts ...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Clofazimine

    go.drugbank.com/drugs/DB00845
    ApprovedInvestigationalWithdrawn

    Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as dapsone, for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye -...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  7. Drug

    Hydroxyurea

    go.drugbank.com/drugs/DB01005
    ApprovedInvestigational

    Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Althou...

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  8. Drug

    Heparin

    go.drugbank.com/drugs/DB01109
    ApprovedInvestigational

    Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibl...

    Products: Hep-Lock U/P
  9. Drug

    Corticotropin

    go.drugbank.com/drugs/DB01285
    ApprovedInvestigationalVet approved

    Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  10. Drug

    Insulin glulisine

    go.drugbank.com/drugs/DB01309
    Approved

    As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin glulisine, to lower glucose levels in the blood. … Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers